Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evaluation of Rucaparib and Companion Diagnostics in the PARP Inhibitor Landscape for Recurrent Ovarian Cancer Therapy
Zachary B. Jenner, Anil K. Sood, Robert L. Coleman
Future Oncology (2016) Vol. 12, Iss. 12, pp. 1439-1456
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Poly(ADP-ribose) polymerase inhibition: past, present and future
Nicola J. Curtin, Csaba Szabó
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 10, pp. 711-736
Closed Access | Times Cited: 403
Exploring and comparing adverse events between PARP inhibitors
Christopher J. Lafargue, Graziela Zibetti Dal Molin, Anil K. Sood, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 1, pp. e15-e28
Open Access | Times Cited: 396
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Sarah J. Hill, Brennan Decker, Emma A. Roberts, et al.
Cancer Discovery (2018) Vol. 8, Iss. 11, pp. 1404-1421
Open Access | Times Cited: 374
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 270
Natural Products and Synthetic Analogs as a Source of Antitumor Drugs
Javad Sharifi‐Rad, Adem Ozleyen, Tugba Boyunegmez Tumer, et al.
Biomolecules (2019) Vol. 9, Iss. 11, pp. 679-679
Open Access | Times Cited: 161
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Xuan Jiang, M Kellis, Weihua Li, et al.
Journal of Cellular and Molecular Medicine (2019) Vol. 23, Iss. 4, pp. 2303-2313
Open Access | Times Cited: 146
Synthetic Lethality in Cancer Therapeutics: The Next Generation
Jeremy Setton, Michael Zinda, Nadeem Riaz, et al.
Cancer Discovery (2021) Vol. 11, Iss. 7, pp. 1626-1635
Open Access | Times Cited: 142
Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies
Wei Zeng, Chi Han, Sarah Mohammed, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 3, pp. 788-808
Closed Access | Times Cited: 21
Drugging the Cancers Addicted to DNA Repair
Jac A. Nickoloff, Dennie V. Jones, Suk‐Hee Lee, et al.
JNCI Journal of the National Cancer Institute (2017) Vol. 109, Iss. 11
Open Access | Times Cited: 149
Advances in the use of PARP inhibitor therapy for breast cancer
Kelly McCann, Sara A. Hurvitz
Drugs in Context (2018) Vol. 7, pp. 1-30
Open Access | Times Cited: 120
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study
Patricia Baxter, Jack M. Su, Arzu Onar‐Thomas, et al.
Neuro-Oncology (2020) Vol. 22, Iss. 6, pp. 875-885
Open Access | Times Cited: 71
Rucaparib: First Global Approval
Yahiya Y. Syed
Drugs (2017) Vol. 77, Iss. 5, pp. 585-592
Closed Access | Times Cited: 80
PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
Stergios Boussios, Afroditi Karathanasi, Deirdre Cooke, et al.
Diagnostics (2019) Vol. 9, Iss. 2, pp. 55-55
Open Access | Times Cited: 66
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
Gianluca Mauri, Sabrina Arena, Salvatore Siena, et al.
Annals of Oncology (2020) Vol. 31, Iss. 9, pp. 1135-1147
Open Access | Times Cited: 66
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
LE Dockery, CC Gunderson, KN Moore
OncoTargets and Therapy (2017) Vol. Volume 10, pp. 3029-3037
Open Access | Times Cited: 63
Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches
Alessandro Mangogna, Giada Munari, Francesco Pepe, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 2, pp. 284-284
Open Access | Times Cited: 21
PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
Mekonnen Sisay, Dumessa Edessa
Gynecologic Oncology Research and Practice (2017) Vol. 4, Iss. 1
Open Access | Times Cited: 57
Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer
Angela Musella, Erlisa Bardhi, Cláudia Marchetti, et al.
Cancer Treatment Reviews (2018) Vol. 66, pp. 7-14
Closed Access | Times Cited: 56
Synthetic Approaches to New Drugs Approved During 2016
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 16, pp. 7004-7031
Closed Access | Times Cited: 56
An update of new small-molecule anticancer drugs approved from 2015 to 2020
Xiaoxia Liang, Pan Wu, Qian Yang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113473-113473
Closed Access | Times Cited: 41
Targeting BRCA and PALB2 in Pancreatic Cancer
Sriram Anbil, Kim A. Reiss
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 3, pp. 346-363
Closed Access | Times Cited: 5
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
Geraldine O’Sullivan Coyne, Alice Chen, Robert Meehan, et al.
Drugs (2017) Vol. 77, Iss. 2, pp. 113-130
Open Access | Times Cited: 46
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer
Jean Siedel, Kari L. Ring, Wei Hu, et al.
Gynecologic Oncology (2021) Vol. 160, Iss. 3, pp. 777-785
Open Access | Times Cited: 29
Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib
Kelly McCann
Future Oncology (2019) Vol. 15, Iss. 15, pp. 1707-1715
Closed Access | Times Cited: 32
Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine
Chong Guo, Chaoying Song, Jiali Zhang, et al.
Genes & Diseases (2020) Vol. 9, Iss. 3, pp. 668-681
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top